Clinical study on prevention of HBV re-infection by entecavir after liver transplantation

• Published in: Clinical transplantation 2012-03, Vol.26 (2), p.208-215
• Main Authors: Cai, Chang-jie, Lu, Min-qiang, Chen, Ying-hua, Zhao, Hui, Li, Min-ru, Chen, Gui-hua
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antiviral Agents - therapeutic use; Biological and medical sciences; Case-Control Studies; Data processing; DNA; DNA, Viral - blood; End Stage Liver Disease - surgery; End Stage Liver Disease - virology; entecavir; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis B Antibodies - blood; Hepatitis B Antigens - blood; hepatitis B recurrence; Hepatitis B virus; Hepatitis B virus - immunology; Hepatitis B, Chronic - complications; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - prevention & control; Human viral diseases; Humans; Infectious diseases; Lamivudine; Lamivudine - therapeutic use; Liver Transplantation; Liver, biliary tract, pancreas, portal circulation, spleen; Male; Medical sciences; Middle Aged; prevention; Secondary Prevention; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the digestive system; Tissue, organ and graft immunology; Viral diseases; Viral hepatitis
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/j.1399-0012.2011.01448.x

Cai C‐j, Lu M‐q, Chen Y‐h, Zhao H, Li M‐r, Chen G‐h. Clinical study on prevention of HBV re‐infection by entecavir after liver transplantation. 
Clin Transplant 2011 DOI: 10.1111/j.1399‐0012.2011.01448.x. 
© 2011 John Wiley & Sons A/S. :  Purpose:  This aims to evaluate the effects of lamivudine (LAM) and entecavir (ETV) in preventing hepatitis B virus (HBV) re‐infection after liver transplantation (LT). Methods:  A retrospective matched case‐control method was used in this study. From June 2005 to May 2007, the patients who received LAM (100 mg qd) or ETV (0.5 mg qd) were chosen. The LAM and ETV groups were matched using a 3:1 ratio based on the factors, such as age, gender, LAM or ETV antiviral duration, primary disease, and HBV DNA levels at the initiation of antiviral therapy. Data on serum HBV markers, HBV DNA, and cumulative recurrence were collected. Results:  Two hundred and fifty‐two patients were enrolled. The average duration of follow‐up was 38.5 and 41.2 months (LAM and ETV groups) (p > 0.05). Duration of pre‐operative antiviral therapy was 30.3 and 25.8 d (LAM and ETV groups) (p > 0.05). The HBV DNA level decreased from 3.89 × 106 to 5.31 × 105 copies/mL before LT in the LAM group, and decreased from 8.74 × 106 to 5.49 × 104 copies/mL in the ETV group (p